CuraCell TX AB announced that the first patient has been successfully included into its ongoing Phase I/IIa clinical trial evaluating the company’s novel autologous Tumor-Infiltrating Lymphocyte (TIL) therapy, CC-38, for patients with metastatic colorectal and metastatic prostate cancer. 

Read the full announcement here.